Skip to content

Serotonin research published in 2014

Page 2 of 2: studies 21 to 39 of 39, newest first. Back to the serotonin overview

Studies

Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling

Journal of Psychopharmacology April 30, 2014 Tobias Buchborn, H. Schröder, V. Höllt et al. 71 citations

A re-balance of postsynaptic serotonin (5-HT) receptor signalling, with an increase in 5-HT1A and a decrease in 5-HT2A signalling, is a final common pathway multiple antidepressants share. Given that the 5-HT1A/2A agonist lysergic acid diethylamide (LSD), when repeatedly applied, selectively downregulates 5-HT2A, but not 5-HT1A receptors, one might expect LSD to similarly re-balance the...

Serotonin 2A Receptor Agonist Binding in the Human Brain with [11C]Cimbi-36

Journal of Cerebral Blood Flow & Metabolism April 30, 2014 Anders Ettrup, Sofi Da Cunha‐bang, Brenda Mcmahon et al. 106 citations

[ 11 C]Cimbi-36 was recently developed as a selective serotonin 2A (5-HT 2A ) receptor agonist radioligand for positron emission tomography (PET) brain imaging. Such an agonist PET radioligand may provide a novel, and more functional, measure of the serotonergic system and agonist binding is more likely than antagonist binding to reflect 5-HT levels in vivo. Here, we show data from a...

DOI: 10.1038/jcbfm.2014.68 (opens in new tab) Serotonin agonist Human brain 5-HT Receptor Endocrinology +1

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

Biological Psychiatry April 26, 2014 Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger et al. 325 citations

BackgroundThe amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change...

Long-lasting alterations in 5-HT2A receptor after a binge regimen of methamphetamine in mice

The International Journal of Neuropsychopharmacology April 24, 2014 Hong‐yi Chiu, Ming‐huan Chan, Mei-Yi Lee et al. 31 citations

The repeated administration of methamphetamine (MA) to animals in a single-day 'binge' dosing regimen produces damage to dopamine and serotonin terminals and psychosis-like behaviours similar to those observed in MA abusers. The present study aimed to examine the effects of MA binge exposure on 5-HT2A receptors, the subtype of serotonin receptors putatively involved in psychosis. ICR male mice...

Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.

ACS Chemical Neuroscience March 19, 2014 Martin Hansen, Karina Phonekeo, James S Paine et al. 125 citations

N-Benzyl substitution of 5-HT2A receptor agonists of the phenethylamine structural class of psychedelics (such as 4-bromo-2,5-dimethoxyphenethylamine, often referred to as 2C-B) confer a significant increase in binding affinity as well as functional activity of the receptor. We have prepared a series of 48 compounds with structural variations in both the phenethylamine and N-benzyl part of the...

DOI: 10.1021/cn400216u (opens in new tab) Full text (opens in new tab) Receptor pharmacology Medicinal chemistry Serotonin receptors Drug discovery

Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists

Molecular & Cellular Proteomics March 18, 2014 Samah Karaki, Carine Bécamel, Samy Murat et al. 73 citations

The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinogenic activity, whereas structurally related agonists with comparable affinity and activity lack...

NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS

Depression and Anxiety March 10, 2014 Ronald S. Duman 213 citations

Stress and depression are associated with atrophy and loss of neurons in limbic and cortical brain regions that could contribute to the symptoms of depression. Typical monoamine reuptake inhibitor antidepressants have only modest efficacy and require long-term treatment, and are only weakly effective in blocking or reversing these structural changes caused by stress. Recent findings demonstrate...

MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).

Human Psychopharmacology: Clinical and Experimental March 2014 Andrew C. Parrott

Human Psychopharmacology recently published my review into the increase in empirical knowledge about the human psychobiology of MDMA over the past 25 years (Parrott, 2013a). Deficits have been demonstrated in retrospective memory, prospective memory, higher cognition, complex visual processing, sleep architecture, sleep apnoea, pain, neurohormonal activity, and psychiatric status. Neuroimaging...

Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Psychopharmacology March 1, 2014 Amy J. Eshleman, Michael J Forster, Katherine M. Wolfrum et al. 72 citations

Psychoactive-substituted phenethylamines 2,5-dimethoxy-4-chlorophenethylamine (2C-C); 2,5-dimethoxy-4-methylphenethylamine (2C-D); 2,5-dimethoxy-4-ethylphenethylamine (2C-E); 2,5-dimethoxy-4-iodophenethylamine (2C-I); 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2); and 2,5-dimethoxy-4-chloroamphetamine (DOC) are used recreationally and may have deleterious side effects. This study compares...

DOI: 10.1007/s00213-013-3303-6 (opens in new tab) Full text (opens in new tab) Phenethylamines Psychoactive compounds Drugs Substances +12

In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users

The International Journal of Neuropsychopharmacology February 14, 2014 Vibe G. Frøkjær, David Erritzøe, Klaus K. Holst et al. 19 citations

Serotonergic signaling is considered critical for an appropriate adaptation to stress. We have previously observed that in healthy volunteers, prefrontal serotonin transporter (SERT) binding is positively associated with hypothalamic-pituitary-adrenal (HPA)-axis output in terms of the cortisol awakening response (CAR). Here, we tested (1) if such a correlation persists in a human model of...

DOI: 10.1017/s1461145714000066 (opens in new tab) Full text (opens in new tab) MDMA Serotonin transporter Clinical psychology Receptor

How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms

The Journal of Clinical Pharmacology January 16, 2014 C. Michael White 58 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible...

Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds

The Annual Review of Pharmacology and Toxicology January 6, 2014 Mark J. Niciu, Ioline D. Henter, David A. Luckenbaugh et al. 166 citations

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar depression. These effects are in direct contrast to the more modest effects seen after weeks of treatment with classic monoaminergic antidepressants. Numerous open-label and case studies similarly validate ketamine's antidepressant...

The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 3, 2014 Patrick Dawson, Jolanta Opacka-Juffry, James D Moffatt et al.

5-APB, commonly marketed as 'benzofury' is a new psychoactive substance and erstwhile 'legal high' which has been implicated in 10 recent drug-related deaths in the UK. This drug was available on the internet and in 'head shops' and was one of the most commonly sold legal highs up until its recent UK temporary ban (UK Home Office). Despite its prominence, very little is known about its...

Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 3, 2014 Brittney M Cox, Mrudang M Shah, Teri Cichon et al.

Adolescents and young adults disproportionately abuse 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'); however, since most MDMA research has concentrated on adults, the effects of MDMA on the developing brain remain obscure. Therefore, we evaluated place conditioning to MDMA (or saline) during late adolescence and assessed anxiety-like behavior and monoamine levels during abstinence. Rats...

Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.

Frontiers in Pharmacology 2014 Petra Amchova, Jana Kučerová, Valentina Giugliano et al.

Depression has been associated with drug consumption, including heavy or problematic cannabis use. According to an animal model of depression and substance use disorder comorbidity, we combined the olfactory bulbectomy (OBX) model of depression with intravenous drug self-administration procedure to verify whether depressive-like rats displayed altered voluntary intake of the CB1 receptor...

Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA.

Heart & Lung 2014 O Davies, B Batajoo-Shrestha, J Sosa-Popoteur et al.

3, 4-methylenedioxymethamphetamine (MDMA), popularly known as "ecstasy" is a synthetic, psychoactive drug used recreationally for its euphoric and "energy increasing" effects. MDMA has been linked to several severe adverse effects including the development of serotonin syndrome and sudden death. Individuals of Asian descent have been shown to have a predisposition for these severe adverse...

Maternal MDMA administration in mice leads to neonatal growth delay

The Journal of Toxicological Sciences 2014 Asuka Kaizaki, Sachiko Tanaka, Takemi Yoshida et al. 18 citations

The psychoactive recreational drug 3,4-methylenedioxymethamphetamine (MDMA) is widely abused. The fact that MDMA induces neurotoxic damage in serotonergic nerve endings is well known. However, the effects of MDMA on pregnant and neonatal animals remain unknown. Therefore, we studied the effects of gestational exposure to MDMA on birth, growth, and behavior of pups. Female BALB/c mice were...

Effects of Stress and MDMA on Hippocampal Gene Expression

BioMed Research International 2014 Georg F. Weber, Bethann N. Johnson, Bryan K. Yamamoto et al. 19 citations

MDMA (3,4-methylenedioxymethamphetamine) is a substituted amphetamine and popular drug of abuse. Its mood-enhancing short-term effects may prompt its consumption under stress. Clinical studies indicate that MDMA treatment may mitigate the symptoms of stress disorders such as posttraumatic stress syndrome (PTSD). On the other hand, repeated administration of MDMA results in persistent deficits...

The Potential Dangers of Using MDMA for Psychotherapy

Journal of Psychoactive Drugs 2014 A. C. Parrott 60 citations

MDMA has properties that may make it attractive for psychotherapy, although many of its effects are potentially problematic. These contrasting effects will be critically reviewed in order to assess whether MDMA could be safe for clinical usage. Early studies from the 1980s noted that MDMA was an entactogen, engendering feelings of love and warmth. However, negative experiences can also occur...